Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
Date:2/20/2008

et revenues increased to 10.2% in 2007 from 9.6% in 2006.

The increase in general and administrative expense in the fourth

quarter and fiscal year 2007 was primarily attributable to higher

personnel costs and bonuses as a result of the increase in headcount.

Operating Income. As a result of the foregoing, operating income decreased by 29.6% to RMB6.1 million (US$0.8 million) in the fourth quarter 2007 from RMB8.7 million for the same period in 2006. Operating margin decreased to 13.4% in the fourth quarter 2007 as compared to 24.8% for the same period in 2006.

Operating income increased by 32.9% to RMB48.5 million (US$6.7 million) in 2007 from RMB36.5 million in 2006. Operating margin decreased to 26.9% in 2007 from 28.6% in 2006.

Other Expense/Income, Net. We recorded other income, net, of RMB9.5 million (US$1.3 million) in fourth quarter 2007 as compared to other expenses, net for the same period in 2006.

We recorded other income, net, of RMB36.5 million (US$5.0 million) in 2007 as compared to other expenses, net, of RMB0.9 million for 2006. We recorded other income, net as compared to other expenses, net due primarily to interest income from the net proceeds we received in our IPO in February 2007 and a decrease in interest expense as our borrowings were fully repaid in 2007.

Income Before Income Tax Expense and Minority Interests. As a result of the foregoing, our income before income tax expense and minority interests increased by 79.2% to RMB15.6 million (US$2.1 million) in the fourth quarter 2007 from RMB8.7 million for the same period in 2006.

Our income before income tax expense and minority interests increased by 138.3% to RMB85.0 million (US$11.7 million) in 2007 from RMB35.7 million in 2006.

Income Tax Expense. We had an income tax credit of RMB2.2 million (US$0.3 million) in the fourth quarter 2007 as compared to an income tax expense of RMB1.6 million for the same period in 2006
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. 3SBio Inc. Announces Change to the Board of Directors
2. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
3. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
5. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
6. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
9. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Tech provides veteran business leadership to deliver new ideas to market. ... ... www.lgeexecs.com [LGE Execs], an Austin based firm formed to ... agreement with the Texas Tech University System (TTUS). The agreement will ...
... - Dr. Yong Shi of Stevens Institute of ... his project titled "MEMS Umbrella-Shaped Actuator with Active ... on scientific/technical merit for three years and will ... is to design, fabricate and test an umbrella-shaped ...
... SAN FRANCISCO, Calif., Sept. 2 Anesiva,Inc. (Nasdaq: ... M.D. has joined,the company as senior vice president ... clinical and regulatory functions., "Bill brings to ... management products, and a medical background in,anesthesiology," said ...
Cached Biology Technology:LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences 2LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences 3Dr. Yong Shi awarded NSF grant 2Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... medical device currently used for intestinal research, the colonsope, ... method has been developed, inspired by the way in ... received her PhD degree from TU Delft based on ... extremely difficult area to navigate through with a medical ...
... drug tamoxifen (Nolvadex®), which can become less effective over ... along with a second drug, according to new research ... Institute (NCI), part of the National Institutes of Health, ... 11, 2006, issue of Cancer Cell*. , Tamoxifen has ...
... Herceptin is borne by other patients whose treatment has to ... week’s BMJ. , New guidance from the National Institute for ... breast cancer, but it provides no extra funding and does ... extra money. This leaves medical staff with difficult decisions to ...
Cached Biology News:Like a snail through the intestinal canal 2Restoring tamoxifen sensitivity in resistant breast cancer cells 2Other patients bear the real cost of Herceptin 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... cell culture scale-up, these culture chambers produce ... 10 9 range and are useful ... flasks. • High mechanical • strength and ... to shipping • Certified nonpyrogenic and sterilized ...
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... recombinant thermostable DNA polymerase obtained by high ... gene in E. coli, Concentration: 5U/ul, Applications: ... Fisher Scientific, the world leader in serving ... make the world healthier, cleaner and safer ...
Biology Products: